144 related articles for article (PubMed ID: 17373905)
1. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.
Madan RA; Arlen PM; Gulley JL
Expert Opin Biol Ther; 2007 Apr; 7(4):543-54. PubMed ID: 17373905
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Gulley JL; Arlen PM; Tsang KY; Yokokawa J; Palena C; Poole DJ; Remondo C; Cereda V; Jones JL; Pazdur MP; Higgins JP; Hodge JW; Steinberg SM; Kotz H; Dahut WL; Schlom J
Clin Cancer Res; 2008 May; 14(10):3060-9. PubMed ID: 18483372
[TBL] [Abstract][Full Text] [Related]
3. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).
Vasir B; Zarwan C; Ahmad R; Crawford KD; Rajabi H; Matsuoka K; Rosenblatt J; Wu Z; Mills H; Kufe D; Avigan D
J Immunother; 2012 Sep; 35(7):555-69. PubMed ID: 22892452
[TBL] [Abstract][Full Text] [Related]
5. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.
Kaufman HL; Kim-Schulze S; Manson K; DeRaffele G; Mitcham J; Seo KS; Kim DW; Marshall J
J Transl Med; 2007 Nov; 5():60. PubMed ID: 18039393
[TBL] [Abstract][Full Text] [Related]
7. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
Gatti-Mays ME; Strauss J; Donahue RN; Palena C; Del Rivero J; Redman JM; Madan RA; Marté JL; Cordes LM; Lamping E; Orpia A; Burmeister A; Wagner E; Pico Navarro C; Heery CR; Schlom J; Gulley JL
Clin Cancer Res; 2019 Aug; 25(16):4933-4944. PubMed ID: 31110074
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
10. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
11. Development of the PANVAC-VF vaccine for pancreatic cancer.
Petrulio CA; Kaufman HL
Expert Rev Vaccines; 2006 Feb; 5(1):9-19. PubMed ID: 16451103
[TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen-based vaccines.
Marshall J
Semin Oncol; 2003 Jun; 30(3 Suppl 8):30-6. PubMed ID: 12881810
[TBL] [Abstract][Full Text] [Related]
13. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.
Morse MA; Niedzwiecki D; Marshall JL; Garrett C; Chang DZ; Aklilu M; Crocenzi TS; Cole DJ; Dessureault S; Hobeika AC; Osada T; Onaitis M; Clary BM; Hsu D; Devi GR; Bulusu A; Annechiarico RP; Chadaram V; Clay TM; Lyerly HK
Ann Surg; 2013 Dec; 258(6):879-86. PubMed ID: 23657083
[TBL] [Abstract][Full Text] [Related]
15. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Mohebtash M; Tsang KY; Madan RA; Huen NY; Poole DJ; Jochems C; Jones J; Ferrara T; Heery CR; Arlen PM; Steinberg SM; Pazdur M; Rauckhorst M; Jones EC; Dahut WL; Schlom J; Gulley JL
Clin Cancer Res; 2011 Nov; 17(22):7164-73. PubMed ID: 22068656
[TBL] [Abstract][Full Text] [Related]
17. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Greiner JW; Zeytin H; Anver MR; Schlom J
Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
20. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]